Phaeochromocytoma

C74.0-1/C74.9/C79.7/D09.3/D35.0/D44.1 + (M8700/0/3/6)


DESCRIPTION

Catecholamine-secreting tumour of the adrenal medulla.

Clinical presentation

Always consider in hypertensive patients who have paroxysmal symptoms:

  • headaches,
  • tremor,
  • GIT symptoms,
  • recurrent chest discomfort,
  • palpitations,
  • sweating, and
  • anxiety.

There is marked inter-individual variation in symptoms.

Patients may also have orthostatic changes in BP.

Diagnosis

24-hour urine acidified with HCl: normetanephrine (NMA), vanillylmandelic acid (VMA), should be ≥ twice normal for a definite diagnosis. Test is best done during a paroxysm, if possible, using at least 2 samples.

There are many drugs, foods and diseases that can falsely elevate or lower NMA/VMA levels; therefore, the clinician must interpret the results in the light of the clinical context and after having taken an accurate history.

Screen:

young hypertensive patients;

hypertensive patients with paroxysmal symptoms; and

patients with:

  • The classic triad of headache, sweating, and tachycardia, whether or not they have hypertension
  • a family history of a phaeochromocytoma,
  • A familial syndrome that predisposes to catecholamine-secreting tumours (e.g., multiple endocrine neoplasia type 2 [MEN2], neurofibromatosis type 1 [NF1], or von Hippel-Lindau [VHL]). or
  • radiologic evidence of an adrenal mass (adrenal incidentaloma) with or without hypertension.

GENERAL MEASURES

Surgical removal of the tumour.

MEDICINE TREATMENT

Once diagnosis is confirmed, initiate medication with immediate referral.

  • Alpha blockers, e.g.:
  • Doxazosin, oral, 4 mg daily.
    • Dose increase above 8 mg daily to control blood pressure may be required.

LoEIII [40]

  • Calcium channel blockers may be added, e.g.:
  • Amlodipine, oral, 5–10 mg daily.

Note:

  • Do not give patients diuretic therapy unless pulmonary oedema is present.
  • β-blockers must be used with extreme caution in the management of phaeochromocytoma, and only after adequate alpha blockade.

LoEIII [41]

REFERRAL

All patients.